Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03489525 · ClinicalTrials.gov registry record · Phase 1
MEDI2228 in Subjects With Relapsed/Refractory Multiple Myeloma
A Phase 1 study, sponsored by MedImmune.
- Completed
- Registry status
- Phase 1
- Development phase
- 107
- Enrollment target
NCT03489525: Completed Phase 1 study, sponsored by MedImmune.
NCT03489525 is a Phase 1 study that has completed, run by MedImmune. The registered enrollment target is 107 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (78% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03489525, a Phase 1 study, has completed, sponsored by MedImmune.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 107 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety, pharmacokinetics and tolerability, describe the dose-limiting toxicities (DLTs), and determine the maximum tolerated dose (MTD) or maximum administered dose (MAD \[in the absence of establishing the MTD\]) for single agent MEDI2228 in adult subjects with multiple myeloma who are either transplant ineligible or post autologous stem cell transplant and are relapsed/refractory.
Primary Outcome
To assess by the occurrence of adverse events (AEs)
Interventions
- BIOLOGICAL Dose Escalation, MEDI2228, ADC (antibody drug conjugate)
- BIOLOGICAL Dose Expansion, MEDI2228, ADC (antibody drug conjugate)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 107 participants |
| Start Date | 2018-05-08 |
| Est. Completion | 2022-03-21 |
| Phase | Phase 1 |
What the finished NCT03489525 record still lists
NCT03489525 is an interventional study that assigns participants to a tested intervention. The registered 107 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (78% higher).
The record links to 0 conditions, and to 2 interventions - of which Dose Escalation, MEDI2228, ADC (antibody drug conjugate) is the first listed.
NCT03489525 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03489525 about?
NCT03489525 is a clinical study titled "MEDI2228 in Subjects With Relapsed/Refractory Multiple Myeloma". The purpose of this study is to assess the safety, pharmacokinetics and tolerability, describe the dose-limiting toxicities (DLTs), and determine the maximum tolerated dose (MTD) or maximum administered dose (MAD \[in the absence of establishing the MTD\]) for single agent MEDI2228 in adult subjects...
What is the current status of trial NCT03489525?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 107 participants. The study started on 2018-05-08. Estimated completion is 2022-03-21.
What interventions are being tested in trial NCT03489525?
The interventions under investigation include: Dose Escalation, MEDI2228, ADC (antibody drug conjugate) (BIOLOGICAL), Dose Expansion, MEDI2228, ADC (antibody drug conjugate) (BIOLOGICAL).
Who is sponsoring clinical trial NCT03489525?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03489525's enrollment target sits among peer trials
107 531st of 2000 higher than 1,470 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05491668 · 107 participants
Physiological Assessment of Severe Coronary Stenosis for Informing Planned PCI
- NCT06041594 · 107 participants · NA
Treating Pulmonary Embolism With Laguna Thrombectomy System (TRUST)
- NCT06081426 · 107 participants · NA
Examining Neurobiological Mechanisms Underlying the Therapeutic Effect of the Ketogenic Diet in Bipolar Disorder (BD)
- NCT06527599 · 107 participants · NA
Screening in Trauma for Opioid Misuse Prevention - an Adaptive Intervention
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI